<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; patented</title>
	<atom:link href="http://www.tapanray.in/tag/patented/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Access Denied, Ethics Demanded: India’s Pharma Detailing at a Turning Point</title>
		<link>http://www.tapanray.in/beyond-influence-a-new-era-of-ethical-medical-detailing-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=beyond-influence-a-new-era-of-ethical-medical-detailing-in-india</link>
		<comments>http://www.tapanray.in/beyond-influence-a-new-era-of-ethical-medical-detailing-in-india/#comments</comments>
		<pubDate>Fri, 13 Jun 2025 00:00:28 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[beyond]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[detailing]]></category>
		<category><![CDATA[DGHS]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[era]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[influence]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[limitations]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[representation]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10913</guid>
		<description><![CDATA[June 11, 2025 — The Economic Times reports that a prominent pharmaceutical industry association has urged the Union Health Ministry to reconsider its directive that bars medical representatives (MRs) from physically meeting doctors in central government hospitals. The industry argues that the move &#8230; <a href="http://www.tapanray.in/beyond-influence-a-new-era-of-ethical-medical-detailing-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/beyond-influence-a-new-era-of-ethical-medical-detailing-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Game is Changing: Ensure Better Treatment Outcomes: Leverage Technology</title>
		<link>http://www.tapanray.in/the-game-is-changing-ensure-better-treatment-outcomes-leverage-technology/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-game-is-changing-ensure-better-treatment-outcomes-leverage-technology</link>
		<comments>http://www.tapanray.in/the-game-is-changing-ensure-better-treatment-outcomes-leverage-technology/#comments</comments>
		<pubDate>Mon, 03 Jun 2019 00:00:38 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[augmentation]]></category>
		<category><![CDATA[basic]]></category>
		<category><![CDATA[changing]]></category>
		<category><![CDATA[Digihaler]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Disruptive]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Leveraging]]></category>
		<category><![CDATA[medication]]></category>
		<category><![CDATA[non-drug]]></category>
		<category><![CDATA[outcome]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[ProAir]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[replacement]]></category>
		<category><![CDATA[reSet]]></category>
		<category><![CDATA[Sandoz]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[Teva]]></category>
		<category><![CDATA[Therapeutics]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[types]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9570</guid>
		<description><![CDATA[Today, several pharma players, mostly ‘encouraged’ by many non-pharma tech companies, are trying to gain, at least, a toehold in the digital health care space. It is visible even within the generic drug industry. Such initiatives, as they gain a &#8230; <a href="http://www.tapanray.in/the-game-is-changing-ensure-better-treatment-outcomes-leverage-technology/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-game-is-changing-ensure-better-treatment-outcomes-leverage-technology/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Policy Execution Gap Limits Access To Affordable Medicines?</title>
		<link>http://www.tapanray.in/pharma-policy-execution-gap-limits-access-to-affordable-medicines/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-policy-execution-gap-limits-access-to-affordable-medicines</link>
		<comments>http://www.tapanray.in/pharma-policy-execution-gap-limits-access-to-affordable-medicines/#comments</comments>
		<pubDate>Mon, 15 Oct 2018 00:00:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2001]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[Association]]></category>
		<category><![CDATA[Ayushman Bharat]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[declaration]]></category>
		<category><![CDATA[Doha]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[execution]]></category>
		<category><![CDATA[gap]]></category>
		<category><![CDATA[HTA]]></category>
		<category><![CDATA[implementation]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[negotiation]]></category>
		<category><![CDATA[NPPP]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[payers]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[scheme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[VBP]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9215</guid>
		<description><![CDATA[“The cost of new drugs is putting increasing pressure on people in both rich and poor countries”- was eloquently expressed in an article, titled “Why do new medicines cost so much, and what can we do about it?”. This was &#8230; <a href="http://www.tapanray.in/pharma-policy-execution-gap-limits-access-to-affordable-medicines/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-policy-execution-gap-limits-access-to-affordable-medicines/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Awaiting The Two To Tango: Pharma Innovation And Public Health Interest</title>
		<link>http://www.tapanray.in/awaiting-the-two-to-tango-pharma-innovation-and-public-health-interest/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=awaiting-the-two-to-tango-pharma-innovation-and-public-health-interest</link>
		<comments>http://www.tapanray.in/awaiting-the-two-to-tango-pharma-innovation-and-public-health-interest/#comments</comments>
		<pubDate>Mon, 02 Jan 2017 00:00:28 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Africa]]></category>
		<category><![CDATA[awaiting]]></category>
		<category><![CDATA[countries]]></category>
		<category><![CDATA[developed]]></category>
		<category><![CDATA[Developing]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[expectancy]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[IGWG]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[life]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[NSSO]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[OSDD]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[pricey]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[source]]></category>
		<category><![CDATA[tango]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tropical]]></category>
		<category><![CDATA[two]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8029</guid>
		<description><![CDATA[“The rewards for the breakthrough drug discovery must be substantial, but if prices are the only mechanism through which returns on research flow, affordability will be compromised,” articulated an article titled, ‘Pharmaceutical Policy Reform &#8211; Balancing Affordability with Incentives for Innovation’, &#8230; <a href="http://www.tapanray.in/awaiting-the-two-to-tango-pharma-innovation-and-public-health-interest/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/awaiting-the-two-to-tango-pharma-innovation-and-public-health-interest/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Price Negotiation For Patented Drugs: Still Continues A Policy Paralysis</title>
		<link>http://www.tapanray.in/price-negotiation-for-patented-drugs-continues-a-policy-paralysis/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=price-negotiation-for-patented-drugs-continues-a-policy-paralysis</link>
		<comments>http://www.tapanray.in/price-negotiation-for-patented-drugs-continues-a-policy-paralysis/#comments</comments>
		<pubDate>Mon, 12 Dec 2016 00:00:22 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[interministerial]]></category>
		<category><![CDATA[negotiation]]></category>
		<category><![CDATA[NPPP]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[policy Paralysis]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8006</guid>
		<description><![CDATA[Many poor and even middle-income patients, who spend their entire life savings for treatment of life-threatening ailments, such as, cancer, have been virtually priced out of the access to patented new drugs, across the world. As articulated by the American &#8230; <a href="http://www.tapanray.in/price-negotiation-for-patented-drugs-continues-a-policy-paralysis/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/price-negotiation-for-patented-drugs-continues-a-policy-paralysis/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Patented Drugs: A Dangerous Pricing Trend Impacting Patient Access</title>
		<link>http://www.tapanray.in/patented-drugs-a-dangerous-pricing-trend-impacting-patient-access/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=patented-drugs-a-dangerous-pricing-trend-impacting-patient-access</link>
		<comments>http://www.tapanray.in/patented-drugs-a-dangerous-pricing-trend-impacting-patient-access/#comments</comments>
		<pubDate>Mon, 11 Jul 2016 00:00:10 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[3d]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[dangerous]]></category>
		<category><![CDATA[Daniel]]></category>
		<category><![CDATA[database]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[irresponsible]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[NPPP]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[profits]]></category>
		<category><![CDATA[ptent]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[section]]></category>
		<category><![CDATA[solution]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Stone]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trend]]></category>
		<category><![CDATA[VL]]></category>
		<category><![CDATA[Voluntary]]></category>
		<category><![CDATA[Windfall]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7721</guid>
		<description><![CDATA[The upcoming trend of jaw dropping high prices for new patented drugs sends a ‘storm signal’ to many stakeholders, especially for its adverse impact on patient access. Even more intriguing, such high and insane prices are being fixed rather arbitrarily, &#8230; <a href="http://www.tapanray.in/patented-drugs-a-dangerous-pricing-trend-impacting-patient-access/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/patented-drugs-a-dangerous-pricing-trend-impacting-patient-access/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Unsustainable New Cancer Drug Prices: Resolution Remains A Far Cry</title>
		<link>http://www.tapanray.in/unsustainable-new-cancer-drug-prices-resolution-remains-a-far-cry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=unsustainable-new-cancer-drug-prices-resolution-remains-a-far-cry</link>
		<comments>http://www.tapanray.in/unsustainable-new-cancer-drug-prices-resolution-remains-a-far-cry/#comments</comments>
		<pubDate>Mon, 13 Apr 2015 00:00:04 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[clinic]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Costs]]></category>
		<category><![CDATA[Coverage]]></category>
		<category><![CDATA[Dekkers]]></category>
		<category><![CDATA[DoP. department of pharmaceuticals]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Far Cry]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[health-economics]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[JAMA]]></category>
		<category><![CDATA[Marjin]]></category>
		<category><![CDATA[Mayo]]></category>
		<category><![CDATA[Nexavar]]></category>
		<category><![CDATA[NICE]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[NPPP 2012]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Patented Drugs Pricing]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[public health foundation]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[section 3d]]></category>
		<category><![CDATA[Sloan-Kettering]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[Universal]]></category>
		<category><![CDATA[unsustainable]]></category>
		<category><![CDATA[value based pricing]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6530</guid>
		<description><![CDATA[Prices of new drugs for the treatment of life-threatening ailments, such as cancer, are increasingly becoming unsustainable, across the world, and more in India. As articulated by the American Society of Clinical Oncology in 2014, this is primarily due to &#8230; <a href="http://www.tapanray.in/unsustainable-new-cancer-drug-prices-resolution-remains-a-far-cry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/unsustainable-new-cancer-drug-prices-resolution-remains-a-far-cry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>An Aggressive New Drug Pricing Trend: What It Means To India?</title>
		<link>http://www.tapanray.in/an-aggressive-new-drug-pricing-trend-what-it-means-to-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=an-aggressive-new-drug-pricing-trend-what-it-means-to-india</link>
		<comments>http://www.tapanray.in/an-aggressive-new-drug-pricing-trend-what-it-means-to-india/#comments</comments>
		<pubDate>Mon, 27 Oct 2014 00:00:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[ABBvie]]></category>
		<category><![CDATA[aggressive]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[capita]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Express]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[Harmony]]></category>
		<category><![CDATA[HCV. Sovaldi]]></category>
		<category><![CDATA[Hepatitis C]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[oop]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[per]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Script]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[VL]]></category>
		<category><![CDATA[Voluntary]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6134</guid>
		<description><![CDATA[A new class and an aggressive drug-pricing trend is now evolving in the global pharmaceutical industry, exerting huge financial pressure on the patients and payers, including governments, especially, in the developed nations of the world. Another aspect of this issue &#8230; <a href="http://www.tapanray.in/an-aggressive-new-drug-pricing-trend-what-it-means-to-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/an-aggressive-new-drug-pricing-trend-what-it-means-to-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Patented Drug Pricing: Relevance To R&amp;D Investments</title>
		<link>http://www.tapanray.in/patented-drug-pricing-relevance-to-rd-investments/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=patented-drug-pricing-relevance-to-rd-investments</link>
		<comments>http://www.tapanray.in/patented-drug-pricing-relevance-to-rd-investments/#comments</comments>
		<pubDate>Mon, 18 Aug 2014 00:00:10 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[AMP]]></category>
		<category><![CDATA[brain]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[relevance R&D]]></category>
		<category><![CDATA[smarter]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5766</guid>
		<description><![CDATA[The costs of most of the new life saving drugs, used in the treatment of dreaded diseases such as cancer, have now started going north at a brisk pace, more than ever before. From the global pharma industry perspective, the &#8230; <a href="http://www.tapanray.in/patented-drug-pricing-relevance-to-rd-investments/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/patented-drug-pricing-relevance-to-rd-investments/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is Credibility Erosion of Pharma Accelerating?</title>
		<link>http://www.tapanray.in/is-credibility-erosion-of-pharma-accelerating/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-credibility-erosion-of-pharma-accelerating</link>
		<comments>http://www.tapanray.in/is-credibility-erosion-of-pharma-accelerating/#comments</comments>
		<pubDate>Mon, 10 Mar 2014 00:00:44 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[accelerating]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[credibility]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[erosion]]></category>
		<category><![CDATA[GlaxoSmithKline]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[J&J]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MHRA]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Teva]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[USV]]></category>
		<category><![CDATA[wockhardt]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5060</guid>
		<description><![CDATA[‘Big Pharma’ now seems to be desperately trying to gain the long lost high moral ground by pushing  hard its gigantic image makeover juggernaut, maintaining a strong pitch on the relevance of stringent Intellectual Property Rights (IPR) in the lives &#8230; <a href="http://www.tapanray.in/is-credibility-erosion-of-pharma-accelerating/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-credibility-erosion-of-pharma-accelerating/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
